Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous gp96 immunotherapy for glioblastoma
ChiCTR-ONC-13003309Phase 4Completed
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jun 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vitespen in glioblastoma (GBM), sponsored by Beijing Tiantan Hospital. Primary endpoints: Safety profile of gp96 and Progression-free survival rate at 6 months. Started Jun 2013; status: completed.
02
Drugs
vitespen
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR-ONC-13003309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-13003309.